Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

809 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC; SUMMIT/CREST Investigators. Lonial S, et al. Among authors: torre c. Blood. 2005 Dec 1;106(12):3777-84. doi: 10.1182/blood-2005-03-1173. Epub 2005 Aug 11. Blood. 2005. PMID: 16099887 Free PMC article. Clinical Trial.
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT, Torre C, McMillan S, Renfroe H, Harvey RD, Lechowicz MJ, Khoury HJ, Flowers CR, Waller EK. Lonial S, et al. Among authors: torre c. Clin Cancer Res. 2010 Oct 15;16(20):5079-86. doi: 10.1158/1078-0432.CCR-10-1662. Epub 2010 Aug 25. Clin Cancer Res. 2010. PMID: 20739431 Clinical Trial.
A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
Lonial S, Hicks M, Rosenthal H, Langston A, Redei I, Torre C, Duenzl M, Feinstein B, Cherry J, Waller EK. Lonial S, et al. Among authors: torre c. Biol Blood Marrow Transplant. 2004 Dec;10(12):848-57. doi: 10.1016/j.bbmt.2004.07.008. Biol Blood Marrow Transplant. 2004. PMID: 15570253 Free article. Clinical Trial.
Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
Lonial S, Akhtari M, Kaufman J, Torre C, Lechowicz MJ, Flowers C, Sinha R, Khoury HJ, Langston AA, Waller EK. Lonial S, et al. Among authors: torre c. Biol Blood Marrow Transplant. 2013 Mar;19(3):460-7. doi: 10.1016/j.bbmt.2012.11.017. Epub 2012 Nov 28. Biol Blood Marrow Transplant. 2013. PMID: 23201472 Free article. Clinical Trial.
Regulation of alloimmune responses by dendritic cell subsets.
Lonial S, Torre C, David E, Harris W, Arellano M, Waller EK. Lonial S, et al. Among authors: torre c. Exp Hematol. 2008 Oct;36(10):1309-17. doi: 10.1016/j.exphem.2008.04.021. Epub 2008 Jul 11. Exp Hematol. 2008. PMID: 18620796 Free article.
809 results